Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). (Q34647409)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

main subject

phase II clinical trial

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Robert A Soslow

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Martee L Hensley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J Kyle Wathen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Dejka M Araujo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Gregory Sutton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Dennis A Priebat

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Suzanne George

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Laurence H Baker

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

18 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1555-1561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

inferred from DOI database lookup

7 January 2021

based on heuristic

Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

inferred from DOI database lookup

7 January 2021

based on heuristic

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27942

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.27942

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23335221%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference